NASDAQ:BLRX BIOLINERX LTD/S Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BIOLINERX LTD/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.56 -0.08 (-4.88 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$1.56Now: $1.56▼$1.6450-Day Range$1.63MA: $1.87▼$2.1652-Week Range$1.06Now: $1.56▼$3.04Volume123,136 shsAverage Volume314,737 shsMarket Capitalization$11.67 millionP/E RatioN/ADividend YieldN/ABeta1.99 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc. to investigate the combination of BL-8040 and Genentech's Atezolizumab in various Phase 1b/2 studies for in various solid tumors and hematologic malignancies. BioLineRx Ltd. was founded in 2003 and is based in Modi'in, Israel.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingBIOLINERX LTD/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.50, BIOLINERX LTD/S has a forecasted upside of 829.5% from its current price of $1.56.Amount of Analyst CoverageBIOLINERX LTD/S has only been the subject of 2 research reports in the past 90 days. Previous Next 3.1 Community Rank Outperform VotesBIOLINERX LTD/S has received 479 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBIOLINERX LTD/S has received 292 “underperform” votes. (Add your “underperform” vote.)Community SentimentBIOLINERX LTD/S has received 62.13% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BIOLINERX LTD/S and other stocks. Vote “Outperform” if you believe BLRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLRX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBIOLINERX LTD/S does not currently pay a dividend.Dividend GrowthBIOLINERX LTD/S does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BIOLINERX LTD/S insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.10% of the stock of BIOLINERX LTD/S is held by insiders.Percentage Held by Institutions42.43% of the stock of BIOLINERX LTD/S is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for BIOLINERX LTD/S are expected to grow in the coming year, from ($1.98) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BIOLINERX LTD/S is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BIOLINERX LTD/S is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBIOLINERX LTD/S has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.77 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLRX Previous Symbol CUSIPN/A CIK1498403 Webwww.biolinerx.com Phone972-8642-9100Debt Debt-to-Equity Ratio0.20 Current Ratio2.40 Quick Ratio2.40Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.46 per share Price / Book0.35Profitability EPS (Most Recent Fiscal Year)($2.55) Net Income$-25,450,000.00 Net MarginsN/A Return on Equity-83.55% Return on Assets-51.62%Miscellaneous Employees51 Outstanding Shares7,478,000Market Cap$11.67 million Next Earnings Date11/9/2020 (Estimated) OptionableNot Optionable $1.56 -0.08 (-4.88 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BLRX News and Ratings via Email Sign-up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. BIOLINERX LTD/S (NASDAQ:BLRX) Frequently Asked Questions How has BIOLINERX LTD/S's stock price been impacted by COVID-19 (Coronavirus)? BIOLINERX LTD/S's stock was trading at $1.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BLRX shares have decreased by 2.5% and is now trading at $1.56. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of BIOLINERX LTD/S? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIOLINERX LTD/S in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for BIOLINERX LTD/S. When is BIOLINERX LTD/S's next earnings date? BIOLINERX LTD/S is scheduled to release its next quarterly earnings announcement on Monday, November 9th 2020. View our earnings forecast for BIOLINERX LTD/S. How were BIOLINERX LTD/S's earnings last quarter? BIOLINERX LTD/S (NASDAQ:BLRX) issued its quarterly earnings data on Thursday, August, 6th. The biotechnology company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.15. View BIOLINERX LTD/S's earnings history. What price target have analysts set for BLRX? 2 brokerages have issued twelve-month price objectives for BIOLINERX LTD/S's shares. Their forecasts range from $11.00 to $18.00. On average, they expect BIOLINERX LTD/S's stock price to reach $14.50 in the next twelve months. This suggests a possible upside of 829.5% from the stock's current price. View analysts' price targets for BIOLINERX LTD/S. Who are some of BIOLINERX LTD/S's key competitors? Some companies that are related to BIOLINERX LTD/S include CohBar (CWBR), Newron Pharmaceuticals (NWPHF), Geovax Labs (GOVX), ProPhase Labs (PRPH), Addex Therapeutics (ADDXF), Acerus Pharmaceuticals (ASPCF), Forward Pharma A/S (FWP), Sernova (SEOVF), IMMURON LTD/S (IMRN), Helix Biopharma (HBPCF), Ceapro (CRPOF), Oragenics (OGEN), Aptorum Group (APM), Pulmatrix (PULM) and Oncternal Therapeutics (ONCT). View all competitors. What other stocks do shareholders of BIOLINERX LTD/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLINERX LTD/S investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), AEterna Zentaris (AEZS), Cannabics Pharmaceuticals (CNBX), Pennsylvania R.E.I.T. (PEI), Gran Tierra Energy (GTE), MassRoots (MSRT) and OrganiGram (OGI). Who are BIOLINERX LTD/S's key executives? BIOLINERX LTD/S's management team includes the following people: Mr. Philip A. Serlin CPA, MBA, Chief Exec. Officer (Age 59)Ms. Mali Zeevi CPA, Chief Financial Officer (Age 43)Dr. Ella Sorani, VP R&D (Age 51)Dr. Abi Vainstein-Haras, VP of Clinical Devel. (Age 44)Advocate Norman Kotler, Internal Enforcement Officer, Gen. Counsel and Corp. Sec. (Age 67) What is BIOLINERX LTD/S's stock symbol? BIOLINERX LTD/S trades on the NASDAQ under the ticker symbol "BLRX." Who are BIOLINERX LTD/S's major shareholders? BIOLINERX LTD/S's stock is owned by a number of retail and institutional investors. Top institutional investors include BVF Inc. IL (22.55%), Psagot Investment House Ltd. (1.56%), Goldman Sachs Group Inc. (0.51%) and Opaleye Management Inc. (0.22%). Which major investors are selling BIOLINERX LTD/S stock? BLRX stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL. Which major investors are buying BIOLINERX LTD/S stock? BLRX stock was acquired by a variety of institutional investors in the last quarter, including Psagot Investment House Ltd., Goldman Sachs Group Inc., and Opaleye Management Inc.. How do I buy shares of BIOLINERX LTD/S? Shares of BLRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BIOLINERX LTD/S's stock price today? One share of BLRX stock can currently be purchased for approximately $1.56. How big of a company is BIOLINERX LTD/S? BIOLINERX LTD/S has a market capitalization of $11.67 million. The biotechnology company earns $-25,450,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. BIOLINERX LTD/S employs 51 workers across the globe. What is BIOLINERX LTD/S's official website? The official website for BIOLINERX LTD/S is www.biolinerx.com. How can I contact BIOLINERX LTD/S? BIOLINERX LTD/S's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The biotechnology company can be reached via phone at 972-8642-9100 or via email at [email protected] This page was last updated on 9/27/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
